|
1
|
El-Serag HB: Hepatocellular carcinoma: An
epidemiologic view. J Clin Gastroenterol. 35 (5 Suppl 2):S72–S78.
2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang BE, Ma WM, Sulaiman A, Noer S,
Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishiro S, Miyakawa
Y, et al: Demographic, clinical, and virological characteristics of
hepatocellular carcinoma in Asia: Survey of 414 patients from four
countries. J Med Virol. 67:394–400. 2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Poon RT: Prevention of recurrence after
resection of hepatocellular carcinoma: A daunting challenge.
Hepatology. 54:757–759. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shiina S, Tateishi R, Arano T, Uchino K,
Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, et al:
Radiofrequency ablation for hepatocellular carcinoma: 10-year
outcome and prognostic factors. Am J Gastroenterol. 107:569–577;
quiz 578. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Foster GR, Irving WL, Cheung MC, Walker
AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson
WT, et al: Impact of direct acting antiviral therapy in patients
with chronic hepatitis C and decompensated cirrhosis. J Hepatol.
64:1224–1231. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ikeda K, Kawamura Y, Kobayashi M, Kominami
Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, et
al: Direct-acting antivirals decreased tumor recurrence after
initial treatment of hepatitis C virus-related hepatocellular
carcinoma. Dig Dis Sci. 62:2932–2942. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kobayashi M, Suzuki F, Fujiyama S,
Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase
Y, et al: Sustained virologic response by direct antiviral agents
reduces the incidence of hepatocellular carcinoma in patients with
HCV infection. J Med Virol. 89:476–483. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Morgan RL, Baack B, Smith BD, Yartel A,
Pitasi M and Falck-Ytter Y: Eradication of hepatitis C virus
infection and the development of hepatocellular carcinoma: A
meta-analysis of observational studies. Ann Intern Med.
158:329–337. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zoulim F, Liang TJ, Gerbes AL, Aghemo A,
Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK,
Terrault NA and Wiktor S: Hepatitis C virus treatment in the real
world: Optimising treatment and access to therapies. Gut.
64:1824–1833. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Younossi ZM, Stepanova M, Afdhal N,
Kowdley KV, Zeuzem S, Henry L, Hunt SL and Marcellin P: Improvement
of health-related quality of life and work productivity in chronic
hepatitis C patients with early and advanced fibrosis treated with
ledipasvir and sofosbuvir. J Hepatol. 63:337–345. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Deterding K, Höner Zu Siederdissen C, Port
K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D,
Mix H, et al: Improvement of liver function parameters in advanced
HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Aliment Pharmacol Ther. 42:889–901. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li DK, Ren Y, Fierer DS, Rutledge S,
Shaikh OS, Lo Re V III, Simon T, Abou-Samra AB, Chung RT and Butt
AA: The short-term incidence of hepatocellular carcinoma is not
increased after hepatitis C treatment with direct-acting
antivirals: An ERCHIVES study. Hepatology. 67:2244–2253.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Reig M, Mariño Z, Perelló C, Iñarrairaegui
M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, et al:
Unexpected high rate of early tumor recurrence in patients with
HCV-related HCC undergoing interferon-free therapy. J Hepatol.
65:719–726. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Conti F, Buonfiglioli F, Scuteri A, Crespi
C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi
G, et al: Early occurrence and recurrence of hepatocellular
carcinoma in HCV-related cirrhosis treated with direct-acting
antivirals. J Hepatol. 65:727–733. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cardoso H, Vale AM, Rodrigues S, Gonçalves
R, Albuquerque A, Pereira P, Lopes S, Silva M, Andrade P, Morais R,
et al: High incidence of hepatocellular carcinoma following
successful interferon-free antiviral therapy for hepatitis C
associated cirrhosis. J Hepatol. 65:1070–1071. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aickin M and Gensler H: Adjusting for
multiple testing when reporting research results: The Bonferroni
vs. Holm methods. Am J Public Health. 86:726–728. 1996.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Prenner SB, VanWagner LB, Flamm SL, Salem
R, Lewandowski RJ and Kulik L: Hepatocellular carcinoma decreases
the chance of successful hepatitis C virus therapy with
direct-acting antivirals. J Hepatol. 66:1173–1181. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tampaki M, Savvanis S and Koskinas J:
Impact of direct-acting antiviral agents on the development of
hepatocellular carcinoma: Evidence and pathophysiological issues.
Ann Gastroenterol. 31:670–679. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nagaoki Y, Imamura M, Nishida Y, Daijo K,
Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, et
al: The impact of interferon-free direct-acting antivirals on
clinical outcome after curative treatment for hepatitis C
virus-associated hepatocellular carcinoma: Comparison with
interferon-based therapy. J Med Virol. 91:650–658. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Innes H, McDonald S, Hayes P, Dillon JF,
Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, et
al: Mortality in hepatitis C patients who achieve a sustained viral
response compared to the general population. J Hepatol. 66:19–27.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wirth TC and Manns MP: The impact of the
revolution in hepatitis C treatment on hepatocellular carcinoma.
Ann Oncol. 27:1467–1474. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hengst J, Strunz B, Deterding K, Ljunggren
HG, Leeansyah E, Manns MP, Cornberg M, Sandberg JK, Wedemeyer H and
Björkström NK: Nonreversible MAIT cell-dysfunction in chronic
hepatitis C virus infection despite successful interferon-free
therapy. Eur J Immunol. 46:2204–2210. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Goossens N and Hoshida Y: Hepatitis C
virus-induced hepatocellular carcinoma. Clin Mol Hepatol.
21:105–114. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Toyoda H, Tada T, Takaguchi K, Senoh T,
Shimada N, Hiraoka A, Michitaka K, Ishikawa T and Kumada T:
Differences in background characteristics of patients with chronic
hepatitis C who achieved sustained virologic response with
interferon-free versus interferon-based therapy and the risk of
developing hepatocellular carcinoma after eradication of hepatitis
C virus in Japan. J Viral Hepat. 24:472–476. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based clinical practice guidelines for hepatocellular
carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC
Guidelines). Hepatol Res. 45:2015 doi: 10.1111/hepr.12464.
PubMed/NCBI View Article : Google Scholar
|
|
28
|
European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of Cancer:
EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
|
|
29
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Watanabe N, Takai K, Imai K, Shimizu M,
Naiki T, Nagaki M and Moriwaki H: Increased levels of serum leptin
are a risk factor for the recurrence of stage I/II hepatocellular
carcinoma after curative treatment. J Clin Biochem Nutr.
49:153–158. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Imai K, Takai K, Nishigaki Y, Shimizu S,
Naiki T, Hayashi H, Uematsu T, Sugihara J, Tomita E, Shimizu M, et
al: Insulin resistance raises the risk for recurrence of stage I
hepatocellular carcinoma after curative radiofrequency ablation in
hepatitis C virus-positive patients: A prospective, case series
study. Hepatol Res. 40:376–382. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Koike Y, Shiratori Y, Sato S, Obi S,
Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S and
Omata M: Risk factors for recurring hepatocellular carcinoma differ
according to infected hepatitis virus-an analysis of 236
consecutive patients with a single lesion. Hepatology.
32:1216–1223. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nagashima I, Hamada C, Naruse K, Osada T,
Nagao T, Kawano N and Muto T: Surgical resection for small
hepatocellular carcinoma. Surgery. 119:40–45. 1996.PubMed/NCBI View Article : Google Scholar
|
